Observational studyEye (London, England)2026
Treatment patterns and long-term outcomes in anti-VEGF-treated macular oedema secondary to retinal vein occlusion: a retrospective observational study.
Observational study in Eye (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Direct randomized evidence comparing ranibizumab and bevacizumab for macular edema secondary to retinal vein occlusion: a systematic review and meta-analysis.BMC ophthalmology · 2026Pooled it
- Early Macular Leakage Resolution Is Associated with Extended Faricimab Dosing in Retinal Vein Occlusion: A BALATON/COMINO Post Hoc Analysis.Ophthalmology and therapy · 2026Article
- Comment on: 'Treatment patterns and long-term outcomes in anti-VEGF-treated macular oedema secondary to retinal vein occlusion: a retrospective observational study'.Eye (London, England) · 2026Article
- Response to: 'Comment on: 'Treatment patterns and long-term outcomes in anti-VEGF-treated macular oedema secondary to retinal vein occlusion: a retrospective observational study".Eye (London, England) · 2026Article
- Early Real-World Experience of Switching to Faricimab for Macular Oedema Secondary to Vein Occlusion.Life (Basel, Switzerland) · 2026Article
- Anti-vascular endothelial growth factor therapy in clinical practice: Real-world scenarios, limitations, and outcomes.Indian journal of ophthalmology · 2026Review
- Visual acuity and retinal thickness outcomes following anti-VEGF therapy in RVO: influence of early vs. delayed treatment.BMC ophthalmology · 2026Observational
- Baseline predictors of visual response and treatment burden after ranibizumab therapy in macular edema secondary to retinal vein occlusion.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesThis study reported real-world visual acuity (VA), treatment patterns, and ocular safety outcomes from patients with macular oedema secondary to branch, central, or hemi-retinal vein occlusion (BRVO, CRVO, HRVO) treated with anti-vascular endothelial growth factor (VEGF).
methodsData were collected from Medisoft electronic medical records across 16 NHS ophthalmology sites in England over 60 months.
results3511/3465 eyes/patients with BRVO and 3568/3514 eyes/patients with CRVO or HRVO were included; <2% of patients had bilateral RVO and had both eyes included. VA change from index anti-VEGF treatment was lower with longer follow-up. In BRVO eyes, mean (95% CI) change in VA from index was +11.2 (10.6, 11.7) approximate Early Treatment Diabetic Retinopathy Study (ETDRS) letters at Month (M)6 and +8.3 (6.7, 10.0) at M60. Mean (95% CI) change in VA for CRVO/HRVO eyes was +11.5 (10.7, 12.3) approximate ETDRS letters at M6 and +7.0 (4.8, 9.2) at M60. Eyes receiving more injections displayed greater average VA gains. Median (Q1-Q3) annual number of anti-VEGF injections was lower in BRVO and CRVO/HRVO eyes with longer follow-up: M12, 7.0 (5.0-8.0) and 6.0 (4.0-8.0); M60, 2.0 (0.0-5.0) and 1.0 (0.0-5.0). Ocular safety outcome incidence through 60 months was low (endophthalmitis, retinal tears, and retinal detachment <1%).
conclusionsVA improvements were observed soon after anti-VEGF treatment, but were lower with longer follow-up through 60 months, alongside lower annual injection numbers, suggesting that current single-target intravitreal anti-VEGFs may not be sufficiently durable for long-term RVO management in routine practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.